Inozyme Pharma’s (INZY) Outperform Rating Reaffirmed at Wedbush
Wedbush reiterated their outperform rating on shares of Inozyme Pharma (NASDAQ:INZY – Free Report) in a report published on Tuesday, RTT News reports. Wedbush currently has a $15.00 price target on the stock. Inozyme Pharma Stock Down 0.3 % INZY stock opened at $5.72 on Tuesday. Inozyme Pharma has a twelve month low of $2.59 […]
More Stories
Transportation Department to Spend Nearly $1 Billion Toward Road Safety
By Naveen Athrappully Transportation Secretary Sean P. Duffy has announced almost $1 billion in funding to “make roads safer for...
Wyoming Congresswoman Who Ousted Liz Cheney Launches Senate Bid
By Bill Pan Rep. Harriet Hageman (R-Wyo.) is running for the Wyoming Senate seat being vacated by Republican Sen. Cynthia...
US Consumers Grow More Optimistic About Future Finances, Recession Fears Retreat
By Tom Ozimek U.S. consumers grew more hopeful about their future financial prospects in December and edged away from worst-case...
ICE Arrests 101 Illegal Alien Truckers in California
By Naveen Athrappully Authorities have arrested 101 illegal immigrant truck drivers from California highways under Operation Highway Sentinel, Immigration and...
Florence Pugh: Net Worth, Salary, and Relationship with Finn Cole
British movies, blockbusters, and even Marvel movies have enabled Florence Pugh to have a strong career in Hollywood. She is...
Macron Affirms Support for Greenland Sovereignty Amid US Interest in Annexation
By Rachel Roberts French President Emmanuel Macron has reaffirmed his support for the sovereignty of the Danish territory of Greenland...